---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-006142"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:35:43.550678+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027

## Summary
- Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.
- Revenue fell to $20.8M from $31.1M, mainly due to end of Calico collaboration.
- Cash, equivalents and marketable securities at Dec 31, 2023: $281.7M; proforma ~$330M with Jan 2024 inflows, funding into 2027.
- Workforce reduced ~30% in Jan 2024; trials for CFT7455 and CFT1946 continue, data expected 2H2024.
- Collaborations: Merck deal up to $2.5B milestone potential; Betta paid $25M, CTA approved in China.

## SEC filing metadata
- accession: 0001628280-24-006142
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/0001628280-24-006142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/cccc-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-006142
- JSON: https://secwatch.observer/filing/0001628280-24-006142.json
- Plain text: https://secwatch.observer/filing/0001628280-24-006142.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/0001628280-24-006142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.